Clinician brief
Half a page, built to be read before an appointment. If something here would not change a clinical decision or the next conversation, it is not on it. The full record, source documents and structured data sit behind the links at the bottom.
Diagnosis
Sites of disease Lungs · mediastinal lymph nodes · liver segment VII (new, Jul 2026).
Also Smouldering myeloma (diagnosed end of 2021, under haematology surveillance); Gilbert's syndrome (can raise bilirubin). Original pathology Clinician letter
Molecular
Key detected tumour alterations APC p.S1415Rfs*4; TP53 p.R342* Commercial sequencing
Platform Oncomine Comprehensive Plus, 517-gene targeted panel, hg19. Not whole genome or whole exome. Reported tumour-only.
Treatment lines
| Dec 21–Feb 22 | Neoadjuvant XELOX ×4 · good partial response |
| Mar–Oct 22 | Primary resected · liver met resected (R0) · adjuvant CAPOX |
| Oct 22–Apr 23 | Lung mets appear, progress · SABR 55 Gy/5 |
| Jun & Aug 24 | Lung ablations (1 left, then 1 left + 4 right) |
| Feb 25 | EBUS confirms mediastinal nodal disease |
| Apr–Jul 25 | FOLFIRI + cetuximab ×6 · good partial response |
| Feb–May 26 | Rechallenge ×6 · good response (CT 12 May) |
| Jul–Aug 26 | Progression during the break · FOLFIRI + cetuximab restarted 19 Aug |
Current regimen
| Chemo day | Standard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after |
| Supportive | Dexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN |
| Other | Citalopram 30 mg (breakfast) · melatonin 60 mg (evening) · metformin MR 500 mg twice daily (from cycle 5 day 7) · loratadine 10 mg |
Off-label and adjuncts
As at 2 November 2026 · Status Disclosed to my oncologist at the 2 Nov review; she confirmed these can be taken alongside the chemotherapy. Originally proposed by my integrative oncologist (private). Clinician letter
Latest imaging
Before that 23 Jul 2026 CT: progression above and below the diaphragm, new liver metastasis · 19 Jun 2026 CT head with contrast: normal · 12 May 2026 CT: good response · 6 Jan 2026 CT: progression. Imaging report
CEA
Bloods out of range
Current plan and open questions
- CEA more than doubled within two weeks of a partial response on CT — 46.5 on 28 Oct, 104.0 on 11 Nov, after sitting at 44–47 since late September. ALP also up, 149 to 166. What is the significance, and does it change the planned Christmas break? Repeat bloods 25 Nov.
- Maintenance since C7 (12 Nov): modified de Gramont + cetuximab to disease progression, irinotecan omitted after the partial response. The UGT1A1 *28/*28 result is part of why.
- Does 5-FU + bevacizumab before Lonsurf keep antibody–drug conjugate trials open?
- Liver lesion local treatment — to revisit at the next scan.
- NGS blood test results, once funding is confirmed.
- Which alteration is the driving event? The panel reports APC p.S1415Rfs*4 and TP53 p.R342* as detected, but it does not designate a driver and no clinician has characterised one on my file. If a driver were formally called, would it change anything actionable?
- NHS whole genome sequencing referral — the testing to date is a 517-gene panel, not WGS or WES.
- Matched tumour/normal sequencing — the tumour panel is reported tumour-only.
Treating team
Named identifiers are not published here. A version carrying them is sent to clinicians directly on request.
Patient-maintained, checked against source documents. Not medical advice.
Sequencing — tumour DNA and RNA, liquid biopsy, germline and exosomal transcriptome, Astron / EXACTA (Astron Health), August 2025 — is set out in full, with the raw variant files, at
fcancerwith.ai/full-record. Germline data is not published openly.
Full record: fcancerwith.ai/full-record ·
Structured data: /data/oneview.json ·
Corrections: fcancerwith.ai/corrections